Pre-Clinical Articles & Analysis: Older

Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...

By Context Therapeutics Inc.

Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...

By Aktiv Pharma Group, Inc

Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...

By Aktiv Pharma Group, Inc

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine ...

By POP Biotechnologies, Inc. (POP BIO)

Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest that onapristone adds to inhibition ...

By Context Therapeutics Inc.

DAYTONA BEACH, Fla., Nov. 1, 2021 /PRNewswire/ -- Koning begins an FDA screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally. "This FDA screening trial is a major ...

By Koning Corporation

Last week (23-25th September) took place the workshop Atrial Signals 2021 http://www.atrial-signals.kit.edu/ at the Karlsruhe Institute of Technology (KIT), thanks to the joint collaboration of the Institute of Biomedical Engineering (IBT) and the Städtisches Klinikum Karlsruhe. Andreu Climent, CEO of Corify Care presented Acorys, our Non-invasive Electrocardiographic Imaging device of the ...

By Corify Care SL

COPENHAGEN, Denmark--(BUSINESS WIRE)--Neurescue, a medical device company developing innovative cardiovascular solutions to improve the outcomes for emergency patients, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market the company’s NEURESCUE® device for temporary occlusion of large vessels, including patients requiring emergency ...

By Neurescue

BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...

By Empatica Inc.

BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...

By Empatica Inc.

Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats. Infectious diseases are disorders caused by organisms — such as bacteria, ...

By Protheragen

Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. These diagnostic services are designed to support the scientific community in identifying, understanding, and ultimately treating rare diseases that ...

By Protheragen

Alfa Chemistry is one of the leading chemical manufacturers and suppliers who has been able to maintain its leadership position in the pharmaceutical sector by offering a broad product portfolio that caters to all aspects of the drug creation process. Always innovative and outstanding, Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building ...

By Alfa Chemistry

Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, is excited to announce the launch of its PCR toolboxes, including rapid PCR kits, enzymes, reagents, and assays. These PCR products will empower researchers in their pursuit of groundbreaking discoveries, providing convenience and ensuring high-quality results in ...

By Amerigo Scientific

Protheragen-ING Lab, a trustworthy GLP service provider, today announced its latest suite of pharmaceutical safety evaluation services. This is a huge development in the drug development landscape and the company uses its ISO9001 certified infrastructure to follow internationally accepted standards for pre-clinical safety testing. Thanks to innovation and need for safer, more effective drugs, the ...

By Protheragen-ING

CD Formulation, a leading contract research and development biotechnology company, is making strides in the realm of oral thin film manufacturing technologies. As a pioneer in drug delivery innovation, the company specializes in crafting cutting-edge oral thin films, demonstrating remarkable expertise across a myriad of formulation techniques. These oral thin film manufacturing methods are ...

By CD Formulation

Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...

By SCIREQ - an emka TECHNOLOGIES Company

Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...

By SCIREQ - an emka TECHNOLOGIES Company

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...

By SCIREQ - an emka TECHNOLOGIES Company

Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its services to assist ...

By Profacgen